I have always wondered why other companies haven't tried to market it to date to phase 3.
There is a report dating back to 2005 Effects of pentosan polysulfate in osteoarthritis of the knee from Perth
It was a success back then so why did no one jump on it back then.
I realize that trials cost heaps of money and take time.
Another study back in 2010 Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis - An open clinical trial was a success from Japan I think so lots of info out there.
So my question is why did Paradigm jump on it and no one else?. As far as I know, Bene provides the injectable solution from their formula. Did paradigm change anything in the chemistry? Thanks for your insight Mozzarc.
PAR General discussion, page-3
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.030(10.9%) |
Mkt cap ! $85.7M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 27.5¢ | 24.0¢ | $429.9K | 1.713M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 161991 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 29634 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
25.0¢ |
Change
-0.030 ( 7.51 %) |
||||
| Open | High | Low | Volume | ||
| 27.0¢ | 27.0¢ | 23.5¢ | 433775 | ||
| Last updated 15.57pm 03/05/2024 ? | |||||
| PAR (ASX) Chart |